Teladoc Health (NYSE:TDOC) Issues Q1 2025 Earnings Guidance

Teladoc Health (NYSE:TDOC) issued an update on its first quarter 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of -0.400–0.150 for the period, compared to the consensus EPS estimate of -0.370. The company issued revenue guidance of $608.0 million-$629.0 million, compared to the consensus revenue estimate of $633.0 million. Teladoc Health also updated its FY 2025 guidance to -1.100–0.500 EPS.

Teladoc Health Stock Down 2.5 %

Shares of TDOC stock traded down $0.28 during trading hours on Wednesday, hitting $10.91. 10,340,108 shares of the company were exchanged, compared to its average volume of 8,008,443. The company has a market capitalization of $1.88 billion, a PE ratio of -1.89 and a beta of 1.04. Teladoc Health has a 52 week low of $6.76 and a 52 week high of $15.95. The business has a 50 day moving average of $10.58 and a two-hundred day moving average of $9.52. The company has a current ratio of 1.73, a quick ratio of 1.69 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. Analysts anticipate that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on TDOC shares. Deutsche Bank Aktiengesellschaft boosted their target price on Teladoc Health from $10.00 to $12.00 and gave the company a “hold” rating in a research note on Friday, November 1st. Barclays increased their target price on shares of Teladoc Health from $10.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. Royal Bank of Canada raised their target price on shares of Teladoc Health from $11.00 to $12.00 and gave the company an “outperform” rating in a research report on Friday, January 24th. The Goldman Sachs Group boosted their price target on shares of Teladoc Health from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Finally, Piper Sandler restated an “overweight” rating and issued a $13.00 price objective (up previously from $11.00) on shares of Teladoc Health in a report on Wednesday, December 4th. Thirteen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $11.81.

Insiders Place Their Bets

In other Teladoc Health news, insider Carlos Nueno sold 2,389 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $11.93, for a total value of $28,500.77. Following the transaction, the insider now directly owns 2,890 shares of the company’s stock, valued at $34,477.70. This represents a 45.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.95% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.